SyntaxBio
Developer of a programmable differentiation platform for stem cell–derived therapies. The company describes a platform that delivers pre-programmed, sequential epigenetic instructions to control multi-step differentiation of stem cells, with the stated goals of accelerating discovery, reducing differentiation complexity, and improving scalability for cell therapy programs. The organization works with biopharma partners via R&D collaborations.
Industries
Nr. of Employees
small (1-50)
SyntaxBio
Products
Cellgorithm Technology
A platform that programs step-wise cellular differentiation by mimicking human development to generate diverse functional cell types.
Cellgorithm Technology
A platform that programs step-wise cellular differentiation by mimicking human development to generate diverse functional cell types.
Services
Collaborative discovery engagements that apply a programmable differentiation platform to accelerate development of stem cell–derived products, including design and delivery of sequential regulators and process optimization for scale.
Collaborative discovery engagements that apply a programmable differentiation platform to accelerate development of stem cell–derived products, including design and delivery of sequential regulators and process optimization for scale.
Expertise Areas
- Stem cell differentiation engineering
- Epigenetic programming of cell fate
- CRISPR-based sequential gene activation
- Cell therapy process optimization and scale-up
Key Technologies
- Epigenetic programming platforms
- CRISPR-Cas systems with sequential guide-RNA activation
- Endogenous gene activation methods
- Stem cell differentiation protocols
News & Updates
Recognition listing Syntax Bio among startups to watch.
Preprint describing a modular approach for programming multistep activation of endogenous genes in stem cells.
Coverage of fundraising for the company.
Press release announcing company launch and investor support.
Article describing use of CRISPR approaches in company technology for manufacturing applications.
Peer-reviewed article on sequential activation of guide RNAs to enable successive CRISPR activities, cited by the company.
Recognition listing Syntax Bio among startups to watch.
Preprint describing a modular approach for programming multistep activation of endogenous genes in stem cells.
Coverage of fundraising for the company.
Press release announcing company launch and investor support.
Article describing use of CRISPR approaches in company technology for manufacturing applications.
Peer-reviewed article on sequential activation of guide RNAs to enable successive CRISPR activities, cited by the company.